Ferring Pharmaceuticals Inc. (US division) is a research-based biopharmaceutical company that offers treatments for patients with infertility, osteoarthritis of the knee, and lower urinary tract disorders. Our parent company, The Ferring Group, was founded in 1950 as a research-driven specialty pharmaceutical company. With worldwide annual sales of approximately $1 billion, this global company focuses on 6 therapeutic areas: urology, infertility, obstetrics, gastroenterology, endocrinology, and osteoarthritis.

The US division of Ferring is the leading provider of gonadotropins for infertility treatment. Products include the foundation of mixed protocol, MENOPUR® (menotropins for injection, USP), and its perfect partner, BRAVELLE® (urofollitropin for injection, purified). Also, Ferring introduced EUFLEXXA™, the first bioengineered injectable hyaluronic acid approved in the US for the treatment of osteoarthritis of the knee. Over the past 10 years, Ferring has been developing a pipeline of urology products, several of which are currently in Phase II or III trials. Ferring also recently acquired and relaunched Prosed® DS, a prescription tablet for the treatment of urinary tract pain and discomfort.